Predicting brain metastases of breast cancer based on serum S100B and serum HER2

Troels Bechmann, Jonna Skov Madsen, Ivan Brandslund, Erik Dalsgaard Lund, Tina Ormstrup, E. H. Jakobsen, Anne Marie Bak Jylling, Karina Dahl Steffensen, Anders Jakobsen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

Brain metastases are a major cause of morbidity and mortality in breast cancer. The aim of the current study was to evaluate the prediction of brain metastases based on serum S100B and human epidermal growth factor receptor 2 (HER2). A total of 107 breast cancer patients were included in the current study from two prospective cohort studies with either elevated serum HER2 levels >15 ng/ml or brain metastases verified by magnetic resonance imaging (MRI) or computer tomography (CT). Following the exclusion of six patients, the remaining 101 patients were divided into two groups: Group 0 (n=55), patients with normal MRI results; and group 1 (n=46), patients with brain metastases. The levels of serum S100B and HER2 in the two groups were analyzed prior to MRI or CT of the brain, and no significant differences were identified in the serum HER2 (P=0.060) or S100B levels (P=0.623) between the groups. The univariate analysis of prognostic factors for brain metastases showed a significant correlation with systemic disease (P30 ng/ml (P=0.002). Only systemic disease (P30 ng/ml were identified to correlate with increased risk of brain metastases, which calls for further investigation.
OriginalsprogEngelsk
TidsskriftOncology Letters
Vol/bind6
Udgave nummer5
Sider (fra-til)1265-1270
ISSN1792-1074
DOI
StatusUdgivet - 2013

Fingeraftryk Dyk ned i forskningsemnerne om 'Predicting brain metastases of breast cancer based on serum S100B and serum HER2'. Sammen danner de et unikt fingeraftryk.

Citationsformater